Skip to main content

Table 1 Semantic criteria of predictive/prognostic breast MRI

From: The potential of predictive and prognostic breast MRI (P2-bMRI)

Criterion Acquisition Assessment Pathophysiological correlate Predictive/prognostic value References
Comment Statistics
Amount of fibroglandular tissue DCE, T2WI Visual (American College of Radiology classes from a to d) or automated Fibroglandular tissue, stromal matrix, dense connective tissue, collagen, elastin, lobules, and ducts One of the strongest independent biomarkers of breast cancer incidence. The prognostic value is proven only for mammography. Similar effect for MRI is expected Relative risk (%: amount of fibroglandular tissue on mammograms) for the four classes: a) 1.79 (< 25%)
b) 2.11 (25–50%)
c) 2.92 (50–75%)
d) 4.64 (> 75%)
[43,44,45]
Background of parenchymal enhancement DCE Visual (1st dynamic scan) or automated Tissue perfusion due to hormonal stimulation and proliferative activity For high-risk women, positive correlation with BC incidence. No association among women with average risk High risk and at least mild background parenchymal enhancement: odds ratio 2.1 [46,47,48,49]
Adjacent vessel sign DCE Visual Hypervascularisation
Neoangiogenesis
Presence of adjacent vessel sign indicates invasive cancer. It is less common in DCIS Invasive cancer or DCIS? DOR 2.7; specificity 72.6% [50, 51]
Destruction of nipple line DCE Visual (Fig. 8) Invasion of the nipple-areola complex “Destruction of nipple line” is associated with nodal-positive breast cancer Is this cancer likely to show lymph node metastasis? DOR 2.5; specificity 88.5% [52, 53]
Oedema T2WI Visual (Fig. 6)
Perifocal
Prepectoral
Subcutaneous
Diffuse
Changes in the tumour habitat
Cytokine effects
Vessel permeability
Lymphovascular dissemination
Pitfalls: double check with patient history; renal, cardiac origin (possible bilateral diffuse oedema of non-neoplastic origin); treatment-related (surgery, radiation therapy)
Presence of “diffuse unilateral oedema” is a strong predictor of nodal-positive and high-grade breast cancer Is this cancer likely to show lymph node metastasis? Specificity 94.9%; DOR2.6
Is this cancer high grade (G3) or not (G1 or G2)?
Specificity 95.5%; DOR 2.4
[39, 52, 54,55,56,57]
Perifocal oedema is also an independent predictor of disease recurrence Is this patient likely to develop disease recurrence? Hazard ratio 2.48
Lesion type DCE Visual according to breast imaging reporting and Data system descriptors: mass, non-mass, or “mixed” (mass and non-mass) Unknown Cancers revealing both mass and non-mass enhancement (“mixed”) are more often associated with lymphovascular invasion (compared to mass or non-mass) Is this cancer associated with lymphovascular invasion? DOR 2.4; specificity 82.7% [58]
Cancers revealing mass-like enhancement are more likely to be HER2-positive (compared to non-mass and mixed) Is this cancer HER2-positive? DOR 2.7; specificity 85.7%
Non-mass invasive ductal cancers are more likely to be low grade (compared to mass and mixed) Is this invasive ductal cancer low grade (G1) or not (G2 or G3)? DOR 9.3; specificity 85.3% [59]
Necrosis sign T2WI Visual: hypointense lesion with hyperintense centre Central colliquative (liquid) necrosis Presence of necrosis sign indicates high-grade invasive cancers Is this cancer high grade (G3) or not (G1 or G2)?
Specificity 94.3%; DOR 3.7
[60]
Skin thickening Unenhanced T1WI Visual Subcutaneous tumour spread, inflammatory tumour Presence of skin thickening indicates high-grade invasive cancers. It is less common in G1 and G2 cancers
Presence of skin thickening is also a strong predictor of lymph node metastasis
Is this cancer likely to show lymph node metastasis? DOR 5.9; specificity 94.5% [52, 53]
Rim sign DCE Visual High microvessel density in the peripheral zone of the vital tumour. Connective tissues, fibrosis, and/or necrosis at central part of the tumour centre Presence of rim sign is associated with an increased risk of lymph node metastasis and high-grade cancer Is this cancer likely to show lymph node metastasis? DOR 2.7; specificity 57.1%
Is this cancer high grade (G3) or not (G1 or G2)?
DOR 6.1; specificity 57.5%
[61]
Signal intensity T2WI Visual (Fig. 7): compared to unaffected breast gland parenchyma: hypointense, isointense, or hyperintense Water content of the lesion Hyperintensity on T2WI is associated with elevated Ki-67 and increased cellular proliferation Is this cancer likely to show high (Ki-67 ≥ 14%) or low proliferative activity (Ki-67 < 14)? DOR 2.2; specificity 59.8% [62]
Washout DCE Visual, region of interest, or computer-assisted Hypervascularisation
Neoangiogenesis
Arteriovenous shunts (anarchic vascularisation)
A high washout rate (> 40%) is associated with an increased risk of metachronous metastasis Is this patient likely to develop metachronous metastasis? Sensitivity 100%; negative predictive value 100% [63, 64]
  1. Values reported in the “statistics” column express the probability of a certain outcome (e.g., “nodal metastasis present”), when the given MRI criterion is present (e.g., “washout present”, “mass lesion present”) derive from the referenced literature
  2. DCE Dynamic contrast-enhanced study, DOR Diagnostic odds ratio, HER2 Human epidermal growth factor receptor 2, T1WI T1-weighted imaging, T2WI T2-weighted imaging